Henry Ford Health and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, has announced Henry Ford Health as the first healthcare provider in Michigan to offer Galleri®, GRAIL’s Multi-Cancer Early Detection (MCED) blood test. Henry Ford is among an early group of healthcare providers in the U.S. to offer this MCED test.
The Galleri test is intended for use in those who are at an elevated risk of cancer, such as individuals ages 50 or older. Some younger people may also have an elevated risk of cancer, which is why Henry Ford is making the Galleri test available to patients who are 22 years or older, have no history of cancer or have been cancer-free at least three years, and are not currently pregnant.
Galleri MCED test can detect many cancers that are not commonly screened for today to allow for earlier treatment, and can be incorporated into a routine healthcare visit.
Those who may be interested in the Galleri test should consult with their Henry Ford primary care physician to determine whether the test is appropriate for them.
Because the test is not currently covered by insurance, the Galleri MCED test is an out-of-pocket cost. Patients may be eligible to participate in the interventional PATHFINDER 2 study, which is evaluating the implementation and performance of Galleri in a clinical care setting. The study is currently enrolling individuals who meet the eligibility requirements, which include:
- 50 years or older and receive care at Henry Ford Health.
- Have never been diagnosed with cancer or have been cancer-free at least three years.
- Are not participants in previous or ongoing GRAIL sponsored studies.
- Henry Ford team members and their dependents who are enrolled in a Health Alliance Plan (HAP) of Michigan insurance plan may be eligible for a test at no cost.
To learn more about the Galleri test at Henry Ford Health, visit henryford.com/cancerbloodtest.
Reporting for WGRT – George James
